Cross-Sector entity
Tavalisse is most often covered alongside Rigel Pharmaceuticals, which appears in 3 of these 3 stories. The clearest coverage concentration is market-trends: 2 of 3 stories, with the rest divided among 1 other category. The tracked stories average 2 original sources each.
3 verified stories tracked
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Tavalisse is most often covered alongside Rigel Pharmaceuticals, which appears in 3 of these 3 stories. The clearest coverage concentration is market-trends: 2 of 3 stories, with the rest divided among 1 other category. The tracked stories average 2 original sources each. We currently track 3 Cross-Sector stories that mention Tavalisse, published between March 2, 2026 and March 5, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tavalisse. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Release
Both companies scheduled to report full-year 2025 financial results.
ARCT-032 Phase 1b
Arcturus releases positive interim data for Cystic Fibrosis candidate.
Kostaive Approval
Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.
Rigel Pharmaceuticals and Cumberland Pharmaceuticals reported Q4 results that emphasize commercial execution and a shift toward sustainable profitability. Both companies are leveraging core hospital and oncology assets to navigate a market that increasingly rewards revenue-generating biotechs over speculative R&D.
Rigel and Cumberland Pharmaceuticals reported Q4 results highlighting steady commercial growth in specialty oncology and hospital-based therapies. Both companies are prioritizing portfolio optimization and pipeline advancement to navigate a competitive biotech landscape.
Source: finance.yahoo.com · finance.yahoo.com
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Source: Seeking Alpha · Seeking Alpha
